Every material Form 8-K Pasithea Therapeutics Corp. has filed with the SEC since May 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pasithea Therapeutics said its warrants under symbol KTTAW will expire on September 17, 2026, under their terms and the warrant agency agreement with VStock Transfer, LLC. Unexercised warrants will stop being exercisable and will have no further value, and the warrants will cease trading on Nasdaq and be delisted and deregistered. The company's common stock, KTTA, will continue to trade on Nasdaq.
Warrants (KTTAW) expire on September 17, 2026
Unexercised warrants cease to be exercisable and have no further value
Warrants to be removed from Nasdaq listing via Form 25 filing
Pasithea Therapeutics Corp. received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, moving the deadline from August 19, 2026 to February 16, 2027. The company says it may consider a reverse stock split, and if it does not regain compliance, Nasdaq could begin delisting proceedings, though the company says there is no assurance it will meet the new deadline.
Nasdaq letter dated February 20, 2026 flagged closing bid price below $1.00 for 30 consecutive business days.
Original compliance deadline was August 19, 2026; extension granted in an August 20, 2026 Nasdaq letter to February 16, 2027.
Company may consider a reverse stock split; if not compliant by the deadline, Nasdaq would issue a delisting notice that the company could appeal to a hearings panel.
Pasithea Therapeutics Corp. appointed Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer, effective May 1, 2026, to oversee clinical development and medical strategy for its lead drug candidate PAS-004 in neurofibromatosis type 1. The Board also approved stock option awards on May 1, 2026, at an exercise price of $0.841 per share, including 1,129,323 options for Dr. Krishnan.
Dr. Krishnan, age 55, previously served as Chief Executive Officer at OncoNano Medicines and as Chief Medical Officer at Arcus Biosciences.
Initial annual base salary of $500,000, with a discretionary bonus of up to 40% of base salary; employment is at-will and includes severance in specified circumstances.
Options for 1,129,323 shares at $0.841 per share vest 33% on the one-year anniversary of the May 1, 2026 grant date, with the remainder vesting quarterly over the following two years.
Four non-employee directors each received options for 152,783 shares at $0.841 per share, vesting in full on the one-year anniversary of the grant date.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Pasithea Therapeutics Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →